CEO Initiative Aims To Reduce Development Time For Alzheimer’s Drugs

March 12, 2013

The Pink Sheet, a leading biopharmaceutical trade publication, wrote the following article on the launch of the Global CEO Initiative:

Read the full article

Why 2020?

USAgainstAlzheimer’s has retained its goal of stopping Alzheimer’s by 2020 rather than endorsing the goal of the National Plan to Address Alzheimer’s Disease that calls for preventing and effectively treating the disease by 2025. While we support the national plan and its goals, we believe, as most every family touched by Alzheimer’s disease believes, that preventing and effectively treating Alzheimer's by 2025 is simply too long a wait for concrete progress. There are promising avenues of drug discovery and development that will, if successful, deliver a means of slowing or deferring Alzheimer's symptoms by 2020. By voicing the urgency felt by so many families, we will pressure researchers and industry to do all in their power to make that happen.

CEO Initiative Aims To Reduce Development Time For Alzheimer’s Drugs

Stay Updated